AmorChem investment of $1.5 million will serve to develop new diagnostic and prognostic tools for acute myeloid leukemia (AML) patients to predict how they should be treated based on the genetic make-up of their tumor. 

This funding is part of a multi-institution initiative led by Dr. Guy Sauvageau, Chief Executive Officer and Principal Investigator of the Institute for Research and Immunology and Cancer (IRIC) at the Université de Montréal and by Dr. Josée Hébert, Associate Investigator at IRIC and Director of the Québec Leukemia Cell Bank and hematologist at Maisonneuve-Rosemont Hospital.

This project received more than $11 million in funding through the Competition on Personalized Health of Genome Canada and Génome Québec in partnership with the Canadian Institutes of Health Research. Please see press release posted on April 17, 2013.


Read the press release.